Prognostic significance of malignant pleural effusions in patients with advanced luminal B breast cancer.
Breast cancer
Clinical features
Luminal B
Malignant pleural effusion
Survival
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
25
08
2024
accepted:
30
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
Though the survival of breast cancer (BC) patients with malignant pleural effusion (MPE) has been studied, this has not been specifically studied in the luminal B subtype. Therefore, this study investigated the characteristics and survival of luminal B-BC patients presenting with MPE. We retrospectively analyzed 141 patients diagnosed with postoperative advanced Luminal B breast cancer, including 54 cases with MPE and 87 cases without MPE at the Tianjin Cancer Hospital from January 2012 to January 2015. We assessed the clinical characteristics between the groups. The mean age of all patients was 47 years, with no significant difference between the two groups. Altogether, 29 (33%), 24 (28%), 28 (32%), 45 (52%), and 10 (11%) patients had lung, liver, bone, lymph node, and chest wall metastases, respectively. In addition. The difference in overall survival between the two groups was not significant (P>0.05). However, cox regression analysis showed that only the tumor clinical stage at initial diagnosis was related to short overall survival. Further, we conducted a subgroup analysis and found that the higher the clinical stage at initial diagnosis in age < 50 years patients, the shorter the overall survival, while age > 50 years patients was not. (P < 0.05). There was no difference in the overall survival between luminal B-BC patients with MPE and those without. Clinical stages at initial diagnosis were an independent prognostic factor for age < 50 years luminal B BC with MPE overall survival. Our results may help clinicians make positive decisions regarding personalized treatment of luminal B-BC with MPE.
Sections du résumé
BACKGROUND
BACKGROUND
Though the survival of breast cancer (BC) patients with malignant pleural effusion (MPE) has been studied, this has not been specifically studied in the luminal B subtype. Therefore, this study investigated the characteristics and survival of luminal B-BC patients presenting with MPE.
METHODS
METHODS
We retrospectively analyzed 141 patients diagnosed with postoperative advanced Luminal B breast cancer, including 54 cases with MPE and 87 cases without MPE at the Tianjin Cancer Hospital from January 2012 to January 2015. We assessed the clinical characteristics between the groups.
RESULTS
RESULTS
The mean age of all patients was 47 years, with no significant difference between the two groups. Altogether, 29 (33%), 24 (28%), 28 (32%), 45 (52%), and 10 (11%) patients had lung, liver, bone, lymph node, and chest wall metastases, respectively. In addition. The difference in overall survival between the two groups was not significant (P>0.05). However, cox regression analysis showed that only the tumor clinical stage at initial diagnosis was related to short overall survival. Further, we conducted a subgroup analysis and found that the higher the clinical stage at initial diagnosis in age < 50 years patients, the shorter the overall survival, while age > 50 years patients was not. (P < 0.05).
CONCLUSIONS
CONCLUSIONS
There was no difference in the overall survival between luminal B-BC patients with MPE and those without. Clinical stages at initial diagnosis were an independent prognostic factor for age < 50 years luminal B BC with MPE overall survival. Our results may help clinicians make positive decisions regarding personalized treatment of luminal B-BC with MPE.
Identifiants
pubmed: 39402620
doi: 10.1186/s12905-024-03396-2
pii: 10.1186/s12905-024-03396-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
562Subventions
Organisme : science and Technology Project of Tianjin Municipal Health Commission
ID : 2023BWKY008
Informations de copyright
© 2024. The Author(s).
Références
Hassan M, M R, Mercer NA, Maskell R, Asciak DJ, McCracken E, et al. Survival in patients with malignant pleural effusion undergoing talc pleurodesis. Lung Cancer. 2019;137:14–8.
Li W, Zheng Y, Wu H, Li X. Breast-conserving therapy versus mastectomy for breast cancer: a ten-year follow-up single-center real-world study. Gland Surg. 2022;11(7):1148–65.
doi: 10.21037/gs-22-142
pubmed: 35935564
pmcid: 9346212
Shameek Gayen. Malignant pleural effusion: presentation, diagnosis, and management. Am J Med. 2022;135(10):1188–92.
doi: 10.1016/j.amjmed.2022.04.017
pubmed: 35576996
Peel AM, Mishra EK. The Psychosocial Impact of Indwelling Pleural catheters: a scoping review. Cureus. 2023;15:e41689.
pubmed: 37575731
pmcid: 10413413
Molina S, Martinez-Zayas G, Sainz PV, et al. Breast and lung effusion survival score models: improving survival prediction in patients with malignant pleural effusion and metastasis. Chest. 2021;160:1075–94.
doi: 10.1016/j.chest.2021.03.059
pubmed: 33852918
pmcid: 8449006
Mark E, Roberts NM, Rahman NA, Maskell AC, Bibby, Kevin G, Blyth JP, Corcoran A, Edey J, McCracken R, Mercer, Eleanor K, Mishra, Andrew G, Nicholson. Farinaz Noorzad, Kirstie Opstad, Maria Parsonage, Andrew E Stanton, Steven Walker. British thoracic Society Guideline for pleural disease. Thorax. 2023;78: 1–42.
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
doi: 10.1038/35021093
pubmed: 10963602
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.
doi: 10.1056/NEJMoa022152
pubmed: 12393820
Ian H, Kunkler LJ, Williams, Wilma JL, Jack DA, Cameron JM, Dixon. Breast-conserving surgery with or without irradiation in early breast Cancer. J N Engl J Med. 2023;388(7):585–94.
doi: 10.1056/NEJMoa2207586
Majid Akrami P, Arasteh T, Eghbali HR, Shahraki S, Tahmasebi V, Zangouri A, Rezaianzadeh, Abdolrasoul Talei. Introducing novel and comprehensive models for predicting recurrence in breast cancer using the group LASSO approach: are estimates of early and late recurrence different? World J Surg Oncol. 2018;16(1):185.
doi: 10.1186/s12957-018-1489-0
pubmed: 30208904
pmcid: 6136222
Leonard Schmiester N, Kristensen A, Frigessi. Aleix Prat, Alvaro Köhn-Luque. Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition.Clin Cancer Res. 2024; 30(17):3779–3787.
Vo TH, Abdelaal EE-S, Jordan E. Orla O’Donovan, Edel A McNeela, Jai Prakash Mehta, Sweta Rani. miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: a systematic review. Biochem Biophys Rep. 2023;37:101588.
pubmed: 38088952
pmcid: 10711031
Xu K, Wang Y, Qi J, et al. Analysis of prognostic factors and clinical characteristics for patients with Limited Stage Small Cell Lung Cancer with Pleural Effusion. Zhongguo Fei Ai Za Zhi. 2018;21(1):16–23. https://doi.org/10.3779/j.issn.1009-3419.2018.01.03 .
doi: 10.3779/j.issn.1009-3419.2018.01.03
pubmed: 29357968
Arellano-Orden E, Romero-Romero B, Sánchez-López V, et al. Survivin is a negative prognostic factor in malignant pleural effusion. Eur J Clin Invest. 2018;48(4). https://doi.org/10.1111/eci.12895 .
Goldhirsch A, Wood WC, Coates AS, et al. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47. https://doi.org/10.1093/annonc/mdr304 .
doi: 10.1093/annonc/mdr304
pubmed: 21709140
pmcid: 3144634
Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/college of American pathologist’s guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195–7. https://doi.org/10.1200/JOP.777003 .
doi: 10.1200/JOP.777003
pubmed: 21037871
pmcid: 2900870
Sofia Molina G, Martinez-Zayas PV, Sainz CH, Leung L, Li HB, Grosu. Roberto Adachi, David E Ost. Breast and lung effusion survival score models: improving survival prediction in patients with malignant pleural effusion and metastasis. Chest. 2021;160(3):1075–94.
pubmed: 33852918
pmcid: 8449006
Cansu E, Önder, Teresa J, Ziegler R, Becker, Sara Y, Brucker AD, Hartkopf T, Engler. André Koch. Advancing Cancer therapy predictions with patient-derived Organoid models of metastatic breast Cancer. Cancers (Basel). 2023;15(14):3602.
doi: 10.3390/cancers15143602
Karampinis I, Dionysopoulou A, Galata C, Almstedt K, Grilli M, Hasenburg A, et al. Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: a systematic literature review and pooled analysis. Thorac Cancer. 2022;13(7):883–8.
Chen L, Meng Z, Zhou Z, Li X, Zhao L, Jia Z, Chen J, Tian Y. Qingju Meng, Yibing Liu. Immunotherapy Combined with Chemotherapy in Relapse metaplastic breast Cancer. Onco Targets Ther. 2023;16:885–90.
doi: 10.2147/OTT.S435958
pubmed: 37927329
pmcid: 10624194
Li S, Li C, Shao W, Liu X. Luhao Sun, Zhiyong Yu. Survival analysis and prognosis of patients with breast cancer with pleural metastasis. Front Oncol. 2023;13:1104246.
doi: 10.3389/fonc.2023.1104246
pubmed: 37197429
pmcid: 10183576
Bielsa S, Salud A, Martínez M, et al. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Intern Med. 2008;19(5):334–9.
doi: 10.1016/j.ejim.2007.09.014
pubmed: 18549935
Yamamura J, Kamigaki S, Fujita J, Osato H, Manabe H, Tanaka Y, et al. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients. BMC Cancer. 2021;21(1):476.
doi: 10.1186/s12885-021-08219-3
pubmed: 33926418
pmcid: 8086318
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer (Oxford Engl 1990). 2020;129:60–70.
doi: 10.1016/j.ejca.2020.01.016
Laura A, Huppert Z, Walker M, Li M-O, Kim J, Callan D, Brandman M, Majure ME, Melisko, Hope S, Rugo S, Behr. A Jo Chien. Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study. Breast Cancer Res Treat. 2023;197(1):137–48.
doi: 10.1007/s10549-022-06771-5
Sara A, Hurvitz R, Hegg W-P, Chung S-A, Im W, Jacot V, Ganju JWY, Chiu B, Xu E, Hamilton S, Madhusudan H, Iwata S, Altintas J-W, Henning S-B, Kim V, Petry C-S, Huang W, Li J-S, Frenel. Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortés. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023, 401(10371):105–117.